Ophthotech

One Penn Plaza
Suite 1924
New York
New York
10119
United States

Tel: 212-845-8200
Fax: 212-845-8250

About Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD, and in combination with anti-VEGF therapy in wet AMD patients.

128 articles about Ophthotech

Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors

1/16/2018

Ophthotech announced today the election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to its Board of Directors, effective immediately.
Ophthotech Reports Third Quarter 2017 Financial and Operating Results

11/8/2017

As of September 30, 2017, the Company had $180.2 million in cash and cash equivalents.
Ophthotech Corporation to Report Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017

10/30/2017

Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a business update.
Ophthotech Provides Update On Zimura Complement Programs For Treatment Of Eye Diseases

9/19/2017
Ophthotech's Wet AMD Drug Fails to Meet Primary Endpoint in Phase III Study

8/15/2017
Ophthotech Reports Second Quarter 2017 Financial And Operating Results

7/26/2017
Ophthotech Expands Focus With Development For Ophthalmic Orphan Diseases

7/26/2017
Ophthotech To Report Second Quarter 2017 Financial Results And Host Conference Call On Wednesday, July 26, 2017

7/21/2017
Ophthotech Reports First Quarter 2017 Financial And Operating Results

5/3/2017
Ophthotech To Report First Quarter 2017 Financial Results And Host Conference Call On Wednesday, May 3, 2017

4/26/2017
Ophthotech Co-Founder and CEO to Step Down, CFO Named New Leader

4/25/2017
Ophthotech Reports Fourth Quarter And Full Year 2016 Financial And Operating Results

2/28/2017
Ophthotech To Report Fourth Quarter And Full Year 2016 Financial Results And Host Conference Call On Tuesday, February 28, 2017

2/22/2017
Struggling to Keep Its Head Above Water: Ophthotech to Review Strategic Alternatives and Shake Up C-Suite

2/1/2017
Battered Ophthotech Cuts 80% of Staff After Failed Clinical Trials

1/18/2017
Ophthotech Clinical Disaster Spurs Massive Layoffs

12/27/2016
Ophthotech Plunges as Wet AMD Drug Combo Trials With Novartis AG Flops in Phase III Studies

12/13/2016
Ophthotech Announces Results From Pivotal Phase 3 Trials Of Fovista In Wet Age-Related Macular Degeneration

12/12/2016
Ophthotech Reports Third Quarter 2016 Financial And Operating Results

11/8/2016
Ophthotech Announces The Publication Of Fovista In Combination With Lucentis Phase 2b Study Results In Ophthalmology, The Journal Of The American Academy of Ophthalmology

10/31/2016